Cardiovascular complications after acute spinal cord injury: pathophysiology, diagnosis, and management

**Julio C. Furlan, M.D., M.B.A., M.Sc., Ph.D.,**¹ ² ³
**And Michael G. Fehlings, M.D., Ph.D., F.R.C.S.C.**¹ ² ³

¹Division of Genetics and Development, Toronto Western Research Institute, University Health Network; ²Spinal Program, Krembil Neuroscience Centre, Toronto Western Hospital, University Health Network; and ³Division of Neurosurgery, Department of Surgery, University of Toronto, Ontario, Canada

Cardiovascular complications in the acute stage following traumatic spinal cord injury (SCI) require prompt medical attention to avoid neurological compromise, morbidity, and death. In this review, the authors summarize the neural regulation of the cardiovascular system as well as the pathophysiology, diagnosis, and management of major cardiovascular complications that can occur following acute (up to 30 days) traumatic SCI. Hypotension (both supine and orthostatic), autonomic dysreflexia, and cardiac arrhythmias (including persistent bradycardia) are attributed to the loss of supraspinal control of the sympathetic nervous system that commonly occurs in patients with severe spinal cord lesions at T-6 or higher. Current evidence-based guidelines recommend: 1) monitoring of cardiac and hemodynamic parameters in the acute phase of SCI; 2) maintenance of a minimum mean arterial blood pressure of 85 mm Hg during the hyperacute phase (1 week after SCI); 3) timely detection and appropriate treatment of neurogenic shock and cardiac arrhythmias; and 4) immediate and adequate treatment of episodes of acute autonomic dysreflexia. In addition to these forms of cardiovascular dysfunction, individuals with acute SCIs are at high risk for deep venous thrombosis (DVT) and pulmonary embolism due to loss of mobility and, potentially, altered fibrinolytic activity, abnormal platelet function, and impaired circadian variations of hemostatic and fibrinolytic parameters. Current evidence supports a recommendation for thromboprophylaxis using mechanical methods and anticoagulants during the acute stage up to 3 months following SCI, depending on the severity and level of injury. Low-molecular-weight heparin is the first choice for anticoagulant prophylaxis in patients with acute SCI. Although there is insufficient evidence to recommend (or refute) the use of screening tests for DVT in asymptomatic adults with acute SCI, this strategy may detect asymptomatic DVT in at least 9.4% of individuals who undergo thromboprophylaxis using low-molecular-weight heparin. Indications and treatment of DVT and acute pulmonary embolism are well established and are summarized in this review. Recognition of cardiovascular complications after acute SCI is essential to minimize adverse outcomes and to optimize recovery. (DOI: 10.3171/FOC.2008.25.11.E13)

**KEY WORDS**
- autonomic dysreflexia
- cardiac arrhythmia
- deep venous thrombosis
- hypotension
- pulmonary embolism
- spinal cord injury

Spinal cord injury may be a devastating event for individuals, who may develop motor and sensory impairment and autonomic dysfunction caudal to the level of injury. In addition, SCI represents a substantial economic burden for society, with estimated treatment costs of $9.7 billion (2006) per year.¹⁷ The prevalence of SCI was estimated to be 280 and 681 individuals with SCIs per million inhabitants in Finland and Australia, respectively.²³,⁸³ The estimated incidence of SCI in North America varies from 27 to 81 cases per million inhabitants per year.¹⁰⁷

Historically, renal and respiratory complications have been considered to be the most frequent adverse events after SCI and the most common causes of death.³⁵ However, more recently, cardiovascular disease has been recognized as the leading cause of death in the acute and chronic stages following SCI.³⁵,³⁹ Management of cardiovascular function is particularly challenging during the acute stage of SCI due to the concurrence of neurogenic shock and the common association with other traumatic injuries that can aggravate hemodynamic instability due to hypovolemia. Additionally, paralyzed patients are a well-recognized risk group for DVT and PE, especially during the acute phase following SCI.⁷⁷,¹⁰⁹

Given the clinical relevance of this topic in the acute care setting, we sought to review current knowledge on the neuroanatomy, pathophysiology, and diagnosis of cardiovascular complications, including altered blood pressure and heart rate abnormalities, as well as VTE in the acute stage (up to 30 days) following traumatic SCI. In this paper we also summarize the current evidence-based
innervation of the cardiovascular system.

Supraspinal Control of the Cardiovascular System

In the brain, a complex neural circuitry in the hypothalamus receives afferent inputs from many brain regions, finely processes them, and eventually modulates the cardiovascular response to different stimuli. There are at least 2 key hypothalamic regions that are involved in cardiovascular control—the dorsomedial hypothalamus and the paraventricular nucleus.22,48 Whereas sympathetic premotor neurons—which project directly to sympathetic preganglionic neurons in the spinal cord—are found in the paraventricular nucleus, they are reportedly missing in the paraventricular hypothalamus where synapses with sympathetic premotor neurons occur at the supraspinal levels.22,48 Descending pathways mediating sympathetic influences from the dorsomedial hypothalamus originate in different groups of sympathetic premotor neurons that are reportedly located in the rostral ventrolateral medulla and raphe pallidus.73,96 Activation of neurons in the dorsomedial hypothalamus evokes a variety of responses including increased activity of sympathetic nerve activity in the heart, kidney, and other organs.22,48 Sympathetic vasomotor activation mainly through the rostral ventrolateral medulla (and slightly via the raphe pallidus) results in an increase in ABP, whereas sympathetic cardiac activation largely via the raphe pallidus (and slightly through direct influence from the dorsomedial hypothalamus) causes an increase in heart rate.48 Central serotonin 1A receptors and γ-aminobutyric acid, which were identified in both rostral ventrolateral medulla and raphe pallidus medullary areas, are deemed to be critical in the modulation of the cardiovascular response to various stimuli.47,82,89

In addition to the activity of the dorsomedial hypothalamus neurons, the inputs of the paraventricular nucleus neurons, adjacent to the third ventricle, in the hypothalamus are of great importance for cardiovascular regulation.25 The vagus nerve (cranial nerve X), which is the afferent pathway to the brain for atrial volume receptors, has its first synapse in the nucleus tractus solitarius of the medulla oblongata.29 Inputs from the nucleus tractus solitarius evoke the neuronal activity of the paras-
Cardiovascular complications in the acute stage after SCI

ventricular nucleus, including magnocellular peptidergic neurohypophyseal neurons that secrete oxytocin and vasopressin. Previous studies have suggested that vasopressin neurons projecting to the spinal cord from the paraventricular nucleus exert an excitatory influence on renal sympathetic preganglionic neurons and are tonically inhibited by a network of γ-aminobutyric acid neurons in the paraventricular nucleus. Moreover, response to plasma volume signals has been associated with activation of the early gene e-fos in several parvocellular neurons that project to sites in the spinal cord and brainstem involved in cardiovascular regulation. Stimulation of various sites within the paraventricular nucleus subnucleus has been shown to increase heart rate via activation of paraventricular nucleus oxytocin pathways projecting to the spine. Also, electrophysiological studies have indicated that oxytocin elicits an excitatory response of sympathetic preganglionic neurons in the upper thoracic spinal cord of rats and affects the activity of sympathetic preganglionic neurons in the lower thoracic cord.

Previous experimental studies in rats indicate that stimulation of cardiac vagal afferents or circulating atrial natriuretic peptide activates some paraventricular nucleus neurons projecting to the spine, whereas others are inhibited. Whereas plasma volume expansion or selective stimulation of venous-atrial junctions reportedly causes a sympathetically mediated increase in heart rate in dogs and rodents, it results simultaneously in a decrease in sympathetic activity to the kidneys and renal vasodilation, as well as increased urine flow and sodium loss. Therefore, there is evidence to strongly indicate that the paraventricular nucleus is a "command center" for the atrial (volume) reflex with paraventricular nucleus cardiac and renal arms as described above.

Contribution of the Spinal Cord and ANS to Cardiovascular Control

The ANS plays a crucial role in the cross talk between the brain and the cardiovascular system to maintain an immensely complex dynamic equilibrium of the internal milieu (or homeostasis). The SNS and parasympathetic nervous system are the 2 divisions of the ANS that integrate complex reflex pathways including sensory receptors, afferent pathways, integration centers in the central nervous system (as noted above), efferent pathways, and target organs (Fig. 1).

Sympathetic afferents originating in ergoreceptors (mechanoreceptors) in skeletal muscles, arterial chemoreceptors, and cardiopulmonary receptors provide excitatory input to the nucleus tractus solitarius. Parasympathetic afferents, originating in baroreceptors of the aortic arch and carotid artery, and receptors of the systemic and pulmonary vessels, the great veins, and the atria provide inhibitory input to the nucleus tractus solitarius via the vagus nerve and glossopharyngeal nerve (Fig. 1).

The efferent pathways in both divisions of the ANS include preganglionic and postganglionic neurons. The preganglionic neurons are interneurons that originate centrally, traverse the ventral roots, and terminate in an ANS ganglion outside the central nervous system. The postganglionic neurons are effector neurons that originate in the ANS ganglion and terminate in an effector organ such as the heart and blood vessels. Whereas the cell bodies of the preganglionic neurons are located in the brain or spinal cord, the cell bodies of the postganglionic neurons lie in autonomic ganglia that are located near the spinal cord or the effector organ. Sympathetic preganglionic fibers may synapse in the paravertebral ganglia of the sympathetic chain, which are located laterally to the vertebral bodies or close to the viscera in prevertebral ganglia. Although all sympathetic preganglionic neurons synapse in the sympathetic chain, which includes the superior cervical ganglion, middle cervical ganglion, stellate ganglion, and thoracic paravertebral ganglia in the regions cranial to the diaphragm, the sympathetic preganglionic fibers to the abdomen and pelvis cross the paravertebral ganglia without synapses to form splanchnic nerves. The latter fibers synapse with sympathetic postganglionic fibers in collateral ganglia prior to joining major arteries on their way to the effector organs. Sympathetic outflow to the effectors in the splanchnic region mostly originates from T-5 to T-9, which forms the greater splanchnic nerve to the celiac ganglion. The postganglionic neurons of the SNS also form visceral nerves (e.g., cardiac nerves) and innervate blood vessels and skin.

Both sympathetic and parasympathetic inputs influence functions of the heart. The cardiac sympathetic preganglionic neurons exit the spinal cord from T-1 to T-6 to synapse with cardiac sympathetic postganglionic neurons in the middle cervical ganglion and stellate ganglion. The parasympathetic neurons from the dorsal motor nucleus of the vagus and the nucleus ambiguous in the medulla oblongata reach the heart via recurrent laryngeal nerves and the vagus nerve. Parasympathetic neurons synapse with postganglionic cells localized in the epicardium or within the cardiac walls adjacent to the sinoatrial or atrioventricular node. Clinically, hyperstimulation of the right vagus nerve makes the heart susceptible to bradycardia, whereas hyperstimulation of the left vagus nerve predisposes the heart to atrioventricular blocks.

Pathophysiology of Cardiovascular Complications Following SCI

Cardiovascular Dysfunction After Supraspinal Decentralization

The intact spinal cord is required for suitable autonomic control of different viscera and organs, including the heart and blood vessels. The degree of sympathetic cardiovascular dysfunction is directly related to the location and severity of SCI. The relationship between cardiovascular dysfunction and severity of injury was shown in several clinical studies and in a postmortem examination of human spinal cord tissue, in which individuals with cervical SCI who developed severe hypotension, bradycardia, and episodes of autonomic dysreflexia in the acute stage postinjury had significantly more extensive areas of degeneration within the spinal cord white matter a few segments caudal to the injury site in comparison with individuals with cervical SCI without significant cardiovascular dysfunction (Figs. 2 and 3).
Fig. 2. Graphs showing parameters of neurogenic shock following acute traumatic cervical SCI in two groups of patients. Hemodynamic and cardiac parameters in patients with SCI are categorized as severe cardiovascular dysfunction as opposed to no/minor cardiovascular dysfunction. Mean values (± standard error of the mean) of heart rate (A) and systolic (B) and diastolic (C) blood pressures within the first 5 weeks following SCI are shown. Asterisks indicate significant differences between both groups of patients. Bpm = beats per minute. Adapted with permission from Furlan JC, Fehlings MG, Shannon P, et al: Descending vasomotor pathways in humans: correlation between axonal preservation and cardiovascular dysfunction after spinal cord injury. J Neurotrauma 20:1351–1363, 2003.
Cardiovascular complications in the acute stage after SCI

Cervical or high-thoracic (T-6 or above) severe SCI deprives patients of supraspinal sympathetic control of cardiovascular functions that include coronary blood flow, cardiac contractility, and heart rate. In this group of patients with SCI, parasympathetic cardiac responses via the vagus nerve are the only supraspinal control of the heart, leading to bradycardia and other cardiac arrhythmias. Partial sympathetic denervation of the heart evokes milder cardiovascular dysfunctions in individuals with minor SCI and injuries between T-1 and T-6. Although normal cardiovascular responses can occur in patients with an SCI caudal to the T-6 level, abnormal peripheral vasomotor responses due to decentralized regulation of vascular tone and blood pressure control are seen in patients with severe SCI at T-6 or a more cranial injury who develop low resting blood pressure, orthostatic hypotension, and loss of diurnal fluctuation of blood pressure. In addition to those blood pressure abnormalities, patients with a severe SCI at T-6 or a more cranial injury can experience episodes of autonomic dysreflexia, which is characterized by a sudden increase in blood pressure when a triggering event occurs.

Although the pathophysiology of abnormal cardiovascular control in patients with acute SCI is not completely understood, at least 5 elements of the autonomic circuits have been identified as potentially contributing factors: 1) disruption of the descending cardiovascular (or vasomotor) pathways; 2) morphological changes in the cardiac and vasomotor sympathetic preganglionic neurons; 3) sprouting and the potential formation of inappropriate synapses with spinal interneurons; 4) abnormal spinal efferents; and 5) development of altered sympathetic neurovascular transmission and smooth muscle responsiveness. Given that many of those anatomical changes occur only in the subacute or chronic stages following SCI, the disruption of the descending cardiovascular (or vasomotor) pathways is the most evident contributing factor for the abnormal cardiovascular control observed during the acute stage after severe SCI at T-6 or a more cranial level.

Disruption of these sympathoexcitatory pathways has been associated with several cardiovascular abnormalities in the acute postinjury stage in experimental studies and in a clinicopathological human study. In an immunohistochemical examination of postmortem spinal cord tissue, individuals who developed severe hypoten-

*Fig. 3. Sections of spinal cord tissue (A–C) and graph (D) demonstrating the association between cardiovascular dysfunction and severity of SCI. A–C: High-thoracic spinal cord sections stained for myelin with Luxol fast blue include a representative case of severe cardiovascular dysfunction in the acute stage after SCI (A), a representative case without significant cardiovascular dysfunction following SCI (B), and a representative control case without neurotrauma (C). A well-defined butterfly-shaped area of gray matter can be observed in all sections. Myelin-containing white matter is stained blue. In sections from cases of SCI (A and B), there are areas of axonal degeneration and myelin loss (pink areas within the white matter, indicated by arrows). Bar = 2 mm. D: Graph shows that there was a significant increase in total area of white matter degeneration (expressed as a percentage of the total spinal cord area) in sections of the spinal cords in individuals with severe cardiovascular dysfunction after SCI, compared with individuals without significant cardiovascular dysfunction following SCI. Adapted with permission from Furlan JC, Fehlings MG, Shannon P, et al: Descending vasomotor pathways in humans: correlation between axonal preservation and cardiovascular dysfunction after spinal cord injury. J Neurotrauma 20:1351–1363, 2003.*
Fig. 4. Images showing the localization of descending vasomotor (cardiovascular) pathways in humans. A: Spinal cord section under low power magnification (× 1.25) that was immunostained for neurofilament 200 to identify axons from an individual who developed severe cardiovascular dysfunction during the acute stage after SCI. Areas of the spinal cord where counting of the preserved axons was conducted are marked by squares that include: dorsal column (DC), Area I, lateral corticospinal tracts (CSTs), and Area II. Bar = 1 mm. B: High magnification (× 20) of different areas of the spinal cord stained with neurofilament 200 from a representative case of severe cardiovascular dysfunction after SCI, a case of SCI without significant cardiovascular dysfunction, and a control case without a history of central nervous system trauma. The brown-stained dots represent cross-sections of spinal axons immunocytochemically identified with neurofilament 200. There was a significant axonal loss within Area I (panel b-1) and the CST (panel c-1) in all individuals with severe cardiovascular dysfunction following SCI. Bar = 50 µm, for all panels in B. Adapted with permission from Furlan JC, Fehlings MG, Shannon P, et al: Descending vasomotor pathways in humans: correlation between axonal preservation and cardiovascular dysfunction after spinal cord injury. J Neurotrauma 20:1351–1363, 2003.
Cardiovascular complications in the acute stage after SCI

Systolic, bradycardia, and autonomic dysreflexia during the acute stage after cervical SCI showed significantly fewer preserved axons within the dorsal aspects of the lateral funiculi (Area I) of spinal cord sections a few segments caudal to the injury site, in comparison with individuals who presented no significant signs and symptoms of abnormal cardiovascular control (Figs. 2 and 4).

Sympathetic decentralization leads to altered regulation of the autonomic function with numerous clinical consequences, regardless of the intact parasympathetic (vagal) afferent and efferent pathways in patients with SCI. Pronounced hypotension and persistent bradycardia, which are commonly observed in patients with acute severe SCI at cervical or high-thoracic levels, are key components of neurogenic shock. The effects of neurogenic shock are reportedly more intense and long lasting in humans (up to 5 weeks) following acute SCI (Fig. 2) in comparison with experimental animals in studies using SCI models. Of note, neurogenic shock in the acute phase of SCI should be distinguished from “spinal shock,” which is characterized by a marked reduction or abolition of somatic and/or reflex functions of the spinal cord caudal to the injury site with a duration from days to 6 weeks postinjury.

**Predisposition to Thromboembolic Events After SCI**

Venous thromboembolism, including DVT and PE, is another important cardiovascular complication that is
Major Cardiovascular Complications in the Acute Stage Following SCI

Orthostatic Hypotension

Low resting blood pressure and orthostatic hypotension more often occur in patients with severe SCI at the cervical or high-thoracic level. Orthostatic hypotension represents an additional drop in ABP when a patient with SCI is positioned upright, especially during the acute stage of SCI. The mechanisms underlying orthostatic hypotension are incompletely understood, even though the evidence suggests that a combination of factors may be involved, including: 1) excessive pooling of blood in the organs and viscera due to reduced efferent sympathetic nervous activity and loss of the reflex vasoconstrictor effect of arterial baroreceptors caudal to the level of injury; 2) lack of the countercacting muscular effects of the lower extremities to venous pooling; 3) reduced plasma volumes as a consequence of hyponatremia; and 4) cardiovascular deconditioning as a result of prolonged bed rest.

In a prospective case series, orthostatic hypotension (defined as a reduction in the baseline systolic blood pressure of at least 20 mm Hg or baseline diastolic blood pressure of at least 10 mm Hg after an orthostatic maneuver) occurred in 74% of the orthostatic maneuvers by physiotherapists during treatment of patients with acute SCI, but signs and symptoms accompanied the blood pressure changes in only 59% of the orthostatic maneuvers. In addition, signs and symptoms were perceived as limiting physiotherapy in one-third of orthostatic maneuvers during treatment of patients with acute SCI. Blurred vision, light-headedness, dizziness, fatigue, restlessness, and dyspnea are among the signs and symptoms of orthostatic hypotension that have been attributed to cerebral hypoperfusion. Although orthostatic hypotension is usually more pronounced in the acute phase following SCI and improves over time, there is evidence that symptomatic episodes of orthostatic hypotension can persist for years after SCI in some patients.

In addition to those predisposing factors related to hypotension following SCI, the timing of surgical decompression of the spinal cord may play an important role in the development of cardiovascular dysfunction. In a retrospective study using data from the Sygen randomized controlled trial, Tuli and colleagues found that the presence of neurogenic shock (systolic blood pressure lower than 90 mm Hg) was associated with a delay in the timing of surgical intervention in patients with cervical motor complete SCI. Those results on neurogenic shock appear to match the preliminary results of the Surgical Treatment for Acute Spinal Cord Injury Study (STASCIS), in which improved motor and sensory recovery was noted in the group of patients who underwent early surgical decompression (within the first 24 hours after SCI) in comparison with patients who underwent delayed surgical intervention. Obviously, further research is needed to examine the potential cause and effect relationship between the timing of surgical intervention and the development of neurogenic shock, because those significant differences reported by Tuli and colleagues could be accounted for by a delay in surgical intervention due to the presence of hemodynamic instability.

Autonomic Dysreflexia

In addition to neurogenic hypotension, patients with
Cardiovascular complications in the acute stage after SCI

Acute SCI at cervical or high-thoracic levels (at T-6 or a more cranial level) may experience sudden episodes of extreme elevated blood pressure accompanied by other signs and/or symptoms of autonomic overactivity in response to noxious or nonnoxious stimuli below the level of injury (so-called “autonomic dysreflexia”). More specifically, severe autonomic dysreflexia can be defined as “an increase in systolic blood pressure of at least 20% associated with a change in heart rate and accompanied by at least one of the following signs (sweating, piloerection, facial flushing), or symptoms (headache, blurred vision, stuffy nose).” Some clinicians have also suggested that the presence of a triggering factor for a severe episode of autonomic dysreflexia, such as bladder distention or bowel impaction, should be identified for the diagnosis of this condition. Whereas severe autonomic dysreflexia raises significant clinical concerns, mild episodes of autonomic dysreflexia in response to various stimuli can occur without being noticed and may be of little clinical relevance. For instance, asymptomatic paroxysmal hypertension was reported in men with SCI during bladder contractions and voiding.

Autonomic dysreflexia is a relatively common cardiovascular complication in the chronic stage, but there is evidence that episodes of autonomic dysreflexia can also occur during the acute phase postinjury. In a case series of 58 patients with acute SCIs treated in the Toronto Western Hospital Spinal Program, the frequency of autonomic dysreflexia in the acute stage following SCI was 5.2% (3 of 58 patients), whereas the adjusted incidence for the population at risk (SCI at T-6 or above) was 5.7% (3 of 53 patients). It is worthwhile to emphasize that the resting systolic and diastolic blood pressures in these patients with acute SCIs is lower than in able-bodied individuals and, therefore, an elevation of 20% in the baseline blood pressure that could be considered virtually within the normal range for able-bodied individuals can be life-threatening for patients with acute SCI. In Fig. 5A the cardiovascular signs of an early episode of autonomic dysreflexia can be seen during 1-day records (at Day 4 after the accident) of blood pressure and heart rate from the medical chart of a 31-year-old female patient who sustained a severe fracture at C2–3 after diving into shallow water. The episode of hypertension was accompanied by headache and blurred vision, which coincided with a full bladder; cardiovascular parameters decreased when her bladder was emptied and her position was changed.

Heart Rate Abnormalities

It is well recognized that acute SCI can provoke altered cardiac electrophysiology and increase susceptibility to cardiac arrhythmias. Sinus bradycardia (a heart rate < 50 beats per minute) is the most common heart rate abnormality in patients in the acute stage following SCI (Fig. 5B). However, various other irregularities in cardiac rhythm and conduction have been attributed to autonomic instability following SCI, including repolarization changes, atrioventricular blocks, supraventricular tachycardia, ventricular tachycardia, and primary cardiac arrest. Similar to the altered blood pressure control after SCI, development of heart rate abnormalities in patients with acute SCI is associated with severe injury at the cervical or high-thoracic level. Also, the most pronounced changes are observed during the acute phase (ranging from 2 to 6 weeks postinjury), whereas heart rate parameters can improve substantially in the chronic stage.

Numerous experimental and clinical studies have demonstrated the association between heart rate abnormalities and loss of supraspinal sympathetic control of the heart. Using a model of SCI in monkeys, Evans and colleagues reported sinus and atrioventricular nodal bradycardia as the immediate response to spinal cord compression as seen in ECG recordings. Subsequently, the animals presented with a variety of alterations in cardiac rhythm and conduction, which included premature atrioventricular nodal or ventricular beats, atrioventricular dissociation, ventricular tachycardias, and bigeminal and trigeminal rhythms. In humans, individuals with more severe SCI and fewer preserved axons within the dorsal aspects of the lateral funiculi (where descending sympatheoexcitatory vasomotor pathways are located) showed significantly lower mean heart rates within the first 4 weeks following cervical SCI in comparison with individuals who sustained a less severe injury at the cervical level (Figs. 2–4). Using the analysis of heart rate variability in patients with acute SCI and able-bodied individuals, Bunten and colleagues demonstrated that both power and amplitude in the low-frequency analyses were reduced in patients with tetraplegia in comparison with healthy controls, whereas both groups did not significantly differ with regard to mean power and amplitude in the high frequency. Their results on the low and high frequency analyses indicated a loss of sympathetic tone and intact parasympathetic tone in the patients with acute cervical SCI.

Venous Thromboembolism

Without prophylaxis, the frequency of DVT and PE in patients with acute SCI reportedly varied from 12 to 64% when the diagnosis was only based on clinical criteria. In a prospective study in which screening for DVT was performed in the lower extremities within the first 3 weeks after hospital admission using serial impedance plethysmography and contrast venography, 21 (81%) of 26 individuals with acute traumatic SCI, who did not receive thromboprophylaxis, were diagnosed with DVT. Despite advances in the prevention of VTE with evidence-based recommendations for the use of pharmacological thromboprophylaxis in almost all patients during the acute stage after SCI, VTE still represents a potentially life-threatening condition for patients with acute SCI, with a mortality rate of 9.7% during the first year after the injury.

Several diagnostic strategies have been developed for suspected DVT in different patient groups. Contrast venography of the lower limbs is considered the gold standard for diagnosis of DVT, but its invasive nature, potential complications, technical issues, and costs preclude venography from being used routinely. Duplex ultrasonography has become the imaging test of choice to diagnose DVT in the clinical setting, even though its...
relatively low sensitivity for proximal imaging (29%) and for both proximal and distal imaging (18.2%) in patients in the acute stage after SCI is a matter of concern.3,6,9,20 In a recent systematic review, Orbell and colleagues44 indicated that CT or MR venography could overcome the limitations of the ultrasonographic diagnosis of DVT, but further technical refinement is required prior to their use in clinical practice. Impedance plethysmography can be used to diagnose DVT by detecting increased venous outflow resistance in the deep veins of the lower limbs, but its use has been discontinued in many centers due to its relatively low sensitivity for detecting proximal-vein DVT (66%).36 Nuclear medicine techniques such as 111In-labeled platelet scintigraphy, 99mTc-labeled platelet glycoprotein IIb/IIIa receptor antagonist, and 125I-labeled fibrinogen are not currently used in clinical practice because they are costly and are not advantageous in terms of accuracy in comparison with other diagnostic tests.36 The use of radiolabeled fibrinogen has also been limited due to concerns over the safety of injecting blood-derived products.36 Duplex ultrasonography, impedance plethysmography, and venography were considered as practice options—reflecting unclear clinical certainty—in the imaging diagnosis of DVT in the population with SCI in the 2002 Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries from the AANS and CNS.5,6

Testing for D-dimer, which is a marker of endogenous fibrinolysis, may play an important role in ruling out DVT, even though the current evidence does not support the general use of D-dimer testing as a stand-alone test for the diagnosis of DVT.5,6,103 In a randomized clinical trial, Wells and colleagues103 concluded that DVT can be ruled out and ultrasonography testing can be safely omitted in outpatients who are considered clinically unlikely to have DVT (as assessed by the Wells prediction score for DVT) and who have negative D-dimer test results. The Wells prediction score is a clinical model that can be used to predict the pretest probability of DVT in the general population using patients’ symptoms, signs, and previous medical history.103 Based on the Wells prediction score, a diagnostic algorithm for DVT has recently been developed for application in the general population.90 Given that the current guidelines recommend thromboprophylaxis during acute SCI, a validation study is required to determine the value of the Wells prediction score and the diagnostic algorithm in the specific group of patients with acute SCI.

Similar to the diagnosis of DVT, various diagnostic strategies for acute PE have been reported for the general population; these include diagnostic algorithms, which need to be validated for patients with acute SCI.6,9,7,104 In brief, a suspected diagnosis of PE should be investigated by a careful assessment of the patient based on his or her medical history, physical examination results, and potential risk factors, including paralysis.57 In treating patients with a suspected PE, clinicians should also consider additional studies that include the ECG, chest radiography, arterial blood gas analysis, D-dimer testing, echocardiography, cardiac troponin level, and plasma concentration of brain natriuretic peptide, even though the results of these studies are usually not specific for PE.97 More specific imaging studies play a key role in the diagnosis of acute PE, including ventilation-perfusion scanning, contrast-enhanced CT arteriography, MR imaging, and standard pulmonary arteriography.57 In the absence of cardiopulmonary disease, ventilation-perfusion scanning is most likely to be diagnostic in patients with a suspected PE, whereas a normal perfusion lung scan rules out acute PE.5,97 Contrast-enhanced CT arteriography has advantages over ventilation-perfusion scanning because it has a quicker acquisition, provides visualization of nonvascular structures, assesses the venous system for thrombosis, and can be performed simultaneously with CT venography for DVT.34,97

Evidence-Based Prevention and Treatment of Cardiovascular Complications

Management of Cardiac and Hemodynamic Parameters After Acute SCI

The impact of wider access to trauma centers and neurocritical care on mortality and disability after acute SCI is well recognized.36 The most recent Clinical Practice Guidelines of the Consortium for Spinal Cord Medicine are focused on the most important clinical issues, including cardiovascular dysfunctions that can occur within the first 72 hours after acute SCI.20 Level II evidence supports the recommendation of transferring patients with acute SCI as soon as possible to a Level I trauma center as defined by the American College of Surgeons or by regional statute.20 However, the 2002 AANS/CNS guidelines indicated that evidence supports only practice options, indicative of unclear clinical certainty, for treatment of patients with acute SCI in an intensive care unit or similarly monitored setting.5 Similarly, use of cardiac and hemodynamic monitoring equipment to detect cardiovascular dysfunction in patients with acute cervical SCI is recommended as a practice option in the 2002 AANS/CNS guidelines.5 Additional studies would likely support those recommendations in the level of guidelines and standards because the prevention and appropriate treatment of hemodynamic and cardiac irregularities can reduce mortality rates and improve neurological outcomes after acute SCI.

The Clinical Practice Guidelines of the Consortium for Spinal Cord Medicine reported that at least Level II evidence supports recommendations for the prevention and treatment of hypotension (systolic blood pressure < 90 mm Hg) with early appropriate fluid resuscitation, but with avoidance of volume overload, to maintain tissue...
Cardiovascular complications in the acute stage after SCI

perfusion and to resolve shock. The primary treatment for hypotension in patients with acute SCI is fluid resuscitation, even though there is currently no evidence for an appropriate resuscitation endpoint and optimal mean ABP that prevents hypotensive ischemia of the spinal cord. Favorable outcomes were reported in uncontrolled studies that used clinical protocols including fluid resuscitation and use of vasopressors to maintain a minimum mean ABP of 85 mm Hg during the 1st week following SCI. Those recommendations agree with the status of practice options—which reflect unclear clinical certainty—in the management of acute SCI as indicated in the 2002 AANS/CNS guidelines. Indeed, the paucity of evidence indicates a need for further investigation to define optimal mean ABP and the role of pharmacological treatment for hypotension in patients with acute SCI.

Although acute severe SCI at T-6 or a more cranial level is a major predisposing factor for neurogenic shock, Level III evidence with the highest level of panel agreement in the Consortium for Spinal Cord Medicine supports the recommendation for exclusion of other injuries prior to assigning the cause of hypotension to neurogenic shock. Similarly, the Consortium for Spinal Cord Medicine strongly recommended the clinical practice of timely diagnosis and appropriate treatment of neurogenic shock in the acute phase after SCI, whereas only Level III evidence was found to support this recommendation. In a nonsystematic review, Stevens and colleagues indicated that neurogenic shock should be treated with fluid resuscitation until intravascular volume is restored and, subsequently, use of vasopressors (such as dopamine, norepinephrine, and phenylephrine) may be required.

In addition to hypotension, persistent bradycardia is a common sign of neurogenic shock. Monitoring and treatment of symptomatic bradycardia after acute SCI received the highest level of panel agreement with recommendations based on Level III and Level IV evidence. To counter the loss of sympathetic tone and provide chronotropic cardiac support, vasopressors with both alpha- and beta-adrenergic actions are recommended unless contraindicated.

Management of Acute Autonomic Dysreflexia After Acute SCI

Although the Clinical Practice Guidelines of the Consortium for Spinal Cord Medicine for acute management of autonomic dysreflexia were published approximately a decade ago, this evidence—based set of recommendations remains relevant to clinical practice. The management of an individual with cervical or high-thoracic (T-6 or more cranial) level SCI with signs (including elevated blood pressure) and symptoms of autonomic dysreflexia is summarized in a clinical algorithm that includes monitoring of blood pressure and heart rate after each step. First, the individual should be immediately put in a sitting position if the person is supine. Second, clothing or constrictive devices need to be loosened. Third, potential triggers including bladder distension and bowel impaction should be investigated. If the systolic blood pressure is as elevated as 150 mm Hg or higher, clinicians may consider pharmacological management with a rapid-onset and short-duration antihypertensive agent (such as nifedipine or nitrates) prior to major additional sensory stimulation such as a rectal examination to reduce systolic blood pressure (but not cause hypotension). The resolution of the episode of autonomic dysreflexia should be followed by monitoring of symptoms, blood pressure, and heart rate for at least 2 hours to make sure it does not recur. However, if these management steps provide a poor response or the triggering of the autonomic dysreflexia is not determined, it is recommended to hospitalize the individual for monitoring and pharmacological control of blood pressure as well as further investigation of the potential triggering of the episode of autonomic dysreflexia.

Management of VTE After Acute SCI

Thromboprophylaxis is recognized as the standard of care for patients in the acute stage after SCI according to the evidence-based guidelines of the American College of Chest Physicians, of the AANS/CNS, and of the Consortium for Spinal Cord Medicine. There is Level I evidence to support the use of a mechanical method of prophylaxis such as a compression hose or pneumatic devices in both legs of all patients for at least the first 2 weeks after acute SCI. In addition to mechanical methods of prophylaxis, administration of an adjunct thromboprophylactic drug within the first 72 hours is recommended when there is no evidence of active bleeding or coagulopathy. Low-molecular-weight heparin is the first choice for pharmacological thromboprophylaxis in patients with acute SCI. Alternatively, the guidelines of the American College of Chest Physicians recommend the use of intermittent pneumatic compression combined with either low-dose unfractionated heparin or low-molecular-weight heparin. An adjusted dose of unfractionated heparin appears as the second choice for pharmacological thromboprophylaxis in patients with acute SCI according to the guidelines of the Consortium for Spinal Cord Medicine. Also, at least Level II evidence supports the recommendation for individualized duration of the thromboprophylaxis depending on the patient’s need, medical condition, functional status, support services, and risk. In patients with complete motor SCI without major clinical complications, anticoagulant prophylaxis is recommended for 8 weeks based on Level IV evidence. A more prolonged anticoagulant prophylaxis (12 weeks or until discharge from a rehabilitation setting) should be considered if a patient with complete motor SCI shows other risk factors for VTE including lower limb fracture, obesity, advanced age (> 70 years), heart failure, active cancer, or a previous history of thrombosis. Of note, the AANS/CNS guidelines recommend a 3-month duration of thromboprophylaxis as a practice option, which reflects unclear clinical certainty, based on the evidence in the literature. The use of an inferior vena cava filter is indicated only when pharmacological thromboprophylaxis has failed, there is a contraindication to anticoagulation (active bleeding), the patient’s cardiopulmonary reserve is poor after complete motor high cervical (C-2 or C-3) SCI, or thrombosis in the inferior vena cava develops despite anticoagulant prophylaxis.
A recent systematic review studied the role of screening tests for DVT in asymptomatic adults with acute SCI who undergo pharmacological thromboprophylaxis. In this group of patients, the current evidence is insufficient to support or refute a recommendation for routine screening. However, at least Level II evidence suggests that the use of a screening test might detect asymptomatic DVT in at least 9.4% of patients with acute SCI who undergo thromboprophylaxis with low-molecular-weight heparin during this acute stage. In another recently published systematic review of 45 selected studies, Goodacre and colleagues indicated that all of the diagnostic tests showed a poorer performance in asymptomatic patients because thrombi in those individuals are likely to be smaller and more distal. However, only a few studies have focused on asymptomatic patients who undergo anticoagulant prophylaxis during the acute stage after SCI. Also, the efficacy of the evidence-based guidelines in the prevention of VTE might be underestimated due to several barriers against their implementation. Using data from the HealthFacts database in the United States, Yu and colleagues reported that only 4 (9.1%) of 44 patients with acute SCI who were admitted to a hospital between January 2001 and March 2005 received a guideline-recommended type of prophylaxis. Among the 40 noncompliant patients, 31 (77.5%) received no prophylaxis and 9 received some prophylaxis for an inadequate duration. Similarly, Burns and colleagues found that publication and implementation of guidelines for prevention of VTE among patients with SCI had a modest effect on practice in 6 Veterans Affairs SCI medical centers.

When a patient is diagnosed with VTE, pharmacological treatment is required unless there is a serious contraindication. To reduce the risk of recurrent DVT, postthrombotic syndrome, and development of PE, intravenous or subcutaneous heparin should be immediately initiated and, subsequently, replaced by treatment with oral warfarin for a period of time ranging from 6 weeks to 6 months. Given that the use of anticoagulation treatment involves a relatively significant risk of hemorrhage, clinicians need to weigh the potential benefits and risks for each patient in the process of decision making.

When acute PE is diagnosed, the patient should be treated with parenteral anticoagulation therapy unless it is contraindicated. Subcutaneous administration of low-molecular-weight heparin or the pentasaccharide fondaparinux (a highly selective indirect inhibitor of factor Xa) or intravenous unfractionated heparin is recommended for the first 5 days in patients with a diagnosis of PE (or even in patients with a high suspicion of PE if the risk of bleeding is not excessive) until the international normalized ratio is in the therapeutic range of 2.0 to 3.0 for 2 consecutive days. If standard heparin is the primary anticoagulant drug, a therapeutic range from 1.5 to 2.5 times control for activated partial thromboplastin time is targeted. After reaching a consistent therapeutic range with a parenteral anticoagulant, only oral warfarin that was initiated on the 1st day of anticoagulant therapy and maintained for 6 months should be sufficient to treat the PE and prevent complications and other thromboembolic events.

**Conclusions**

Cardiovascular complications commonly occur following severe SCI. Loss of supraspinal control of the SNS is the major cause of cardiac dysfunction and hemodynamic instability in patients following SCI. These physiological changes are much more common in individuals with complete motor SCI at or rostral to T-6. The most common cardiovascular dysfunctions following acute SCI include supine and orthostatically induced hypotension, autonomic dysreflexia, and cardiac arrhythmias (including persistent bradycardia). Evidence-based guidelines emphasize 4 key interventions to minimize the deleterious effects of cardiovascular dysfunction following acute SCI: 1) monitoring of cardiac and hemodynamic parameters in the acute phase; 2) maintenance of a minimum mean ABP of 85 mm Hg; 3) timely detection and appropriate treatment of neurogenic shock and cardiac arrhythmias; and 4) immediate and adequate treatment of episodes of acute autonomic dysreflexia.

In addition to cardiovascular dysfunction, individuals with acute SCI are at increased risk for VTE due to immobilization (stasis) and, potentially, altered fibrinolytic activity, abnormal platelet function, and impaired circadian variations of hemostatic and fibrinolytic parameters. Current evidence strongly supports the recommendations for thromboprophylaxis using mechanical methods and anticoagulants during the acute stage up to 3 months following SCI, depending on the severity and level of injury. Low-molecular-weight heparin is the first choice for anticoagulant prophylaxis in patients with acute SCI. When DVT or PE is diagnosed, prompt initiation of heparin is usually required unless there is a serious contraindication. Clinicians need to maintain a heightened awareness of cardiovascular dysfunction following acute SCI to intervene proactively and optimize clinical outcomes.

**Disclaimer**

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

**Acknowledgments**

This work was supported by the Krembil Chair in Neural Repair and Regeneration, Toronto Western Research Institute and University of Toronto, held by Michael G. Fehlings, M.D., Ph.D., F.R.C.S.C.

**References**


*Neurosurg. Focus / Volume 25 / November 2008*
Cardiovascular complications in the acute stage after SCI


*Neurosurg, Focus / Volume 25 / November 2008*
Cardiovascular complications in the acute stage after SCI


Manuscript submitted July 10, 2008. Accepted September 22, 2008. Address correspondence to: Michael G. Fehlings, M.D., Ph.D., F.R.C.S.C., Toronto Western Hospital, 399 Bathurst Street, 4W449, Toronto, Ontario, Canada, MST 2S8. email: michael.fehlings@uhn.on.ca.